Amerika, Afurika y’epfo n’ibihugu byo mu muryango w’ubumwe bw’Uburayi (EU/UE), byabaye bihagaritse gukingira abantu n’urukingo rwa Johnson & Johnson (J&J) rwa Covid-19, nyuma y’amakuru yo kuvura kw’amaraso kudakunze kubaho.
Abantu batandatu bagaragaje icyo kibazo mu bantu bahawe doze zirenga miliyoni 6.8, nkuko ikigo cy’Amerika kigenzura ubuziranenge bw’ibiribwa n’imiti (FDA) cyabivuze.
Urukingo rwa Johnson & Johnson rwabaye ruhagaritswe muri EU, aho rwari rwatangiye gutangwa muri iki cyumweru.
Bikurikiye ibindi nk’ibi byabaye ku rukingo rwa AstraZeneca, bigatuma hagabanywa ikoreshwa ryarwo.
Ikigo FDA cyavuze ko kirimo kujya inama ko ruba ruhagaritswe nk'”uburyo bwo kwigengesera cyane”. Cyemeje ko umurwayi umwe yapfuye azize ibibazo byatewe no kuvura kw’amaraso, naho undi akaba arembye.
BBC yatangaje ko abo bantu batandatu bose bagaragaweho kuvura kw’amaraso ni abagore bafite hagati y’imyaka 18 na 48, bagaragaza ibimenyetso by’uko kuvura hagati y’iminsi itandatu na 13 nyuma yo gukingirwa.
Bijyanye n’iyo nama yatanzwe n’ikigo FDA, ahakingirirwa hose muri Amerika bahagaritse gukoresha urwo rukingo kugeza harangiye andi maperereza ku mutekano warwo. Byitezwe ko za leta n’abikorera babikurikiza.
Kugeza ubu Amerika ni yo imaze gutangaza abantu ba mbere benshi ku isi banduye Covid-19, barenga miliyoni 31, n’abarenga 563,000 yishe, aba na bo bakaba ari bo ba mbere benshi ku isi.
Johnson & Johnson ni kompanyi yo muri Amerika, ariko urukingo ahanini rwakorewe ku ishami ryayo riri mu Bubiligi, rizwi nanone nka Janssen.
Bitandukanye n’izindi nkingo zimwe, uru rwo rutangwa inshuro imwe kandi rushobora kubikwa ku bipimo by’ubushyuhe busanzwe bwo muri ‘frigo’. Ibi bituma byoroha cyane kurugeza ahantu hashyushye cyane cyangwa hagoye kugera.
Mu gihe ibihugu byinshi byamaze gutumiza za doze zarwo zibarirwa muri za miliyoni, mu bihugu bicye ni ho rwemejwe ko rwakoreshwa.
Muri Amerika rwahawe uruhushya rwo gukoreshwa ku itariki ya 27 y’ukwezi kwa kabiri, ariko inkingo za Pfizer-BioNTech na Moderna ni zo kugeza ubu zikoreshwa cyane.
iriba.news@gmail.com
